A Prospective Observational Cohort Study of Fetal Immune-Mediated High-Degree Heart Block
Slow Heart Registry
What is the goal of the study?
This is a multi-centered prospective observational study that will address the knowledge gap to guide future management of high-degree immune-mediated AVB to the best of care. The study aims are to document the outcome of patients diagnosed prenatally with immune-mediated 2nd or 3rd degree AVB irrespective of the primary choice of prenatal care. The primary objective will be to determine the rate of transplant-free survival to 1 year of life of fetuses with AVB based on the prenatal management decision: Cohort 1: Fetuses not treated with fluorinated glucocorticoids Cohort 2: Fetuses treated with fluorinated glucocorticoids from the time of immune-mediated AVB diagnosis. Secondary objectives will be to determine The evolution of key clinical findings to birth The changes in prenatal treatment (steroids; beta-mimetics; IVIG) to birth; Prevalence of relevant fetal-maternal events and complications; Gestational age and weight at birth; Postnatal management (pacing; steroids; IVIG); and the clinical evolution to 1-3 years of life (cardiac function; developmental milestones; growth; health).
Who can participate in the study?
Please contact the study team listed below to learn more.